10.3389/fimmu.2018.01953.s001 Zeb R. Zacharias Zeb R. Zacharias Kathleen A. Ross Kathleen A. Ross Emma E. Hornick Emma E. Hornick Jonathan T. Goodman Jonathan T. Goodman Balaji Narasimhan Balaji Narasimhan Thomas J. Waldschmidt Thomas J. Waldschmidt Kevin L. Legge Kevin L. Legge Data_Sheet_1_Polyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus Infections.PDF Frontiers 2018 influenza virus nanovaccine adaptive immunity tissue-resident memory heterosubtypic protection 2018-08-28 04:16:23 Dataset https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Polyanhydride_Nanovaccine_Induces_Robust_Pulmonary_B_and_T_Cell_Immunity_and_Confers_Protection_Against_Homologous_and_Heterologous_Influenza_A_Virus_Infections_PDF/7015712 <p>Influenza A virus (IAV) is a major cause of respiratory illness. Given the disease severity, associated economic costs, and recent appearance of novel IAV strains, there is a renewed interest in developing novel and efficacious “universal” IAV vaccination strategies. Recent studies have highlighted that immunizations capable of generating local (i.e., nasal mucosa and lung) tissue-resident memory T and B cells in addition to systemic immunity offer the greatest protection against future IAV encounters. Current IAV vaccines are designed to largely stimulate IAV-specific antibodies, but do not generate the lung-resident memory T and B cells induced during IAV infections. Herein, we report on an intranasally administered biocompatible polyanhydride nanoparticle-based IAV vaccine (IAV-nanovax) capable of providing protection against subsequent homologous and heterologous IAV infections in both inbred and outbred populations. Our findings also demonstrate that vaccination with IAV-nanovax promotes the induction of germinal center B cells within the lungs, both systemic and lung local IAV-specific antibodies, and IAV-specific lung-resident memory CD4 and CD8 T cells. Altogether our findings show that an intranasally administered nanovaccine can induce immunity within the lungs, similar to what occurs during IAV infections, and thus could prove useful as a strategy for providing “universal” protection against IAV.</p>